Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.3 USD | +0.16% | +3.76% | +7.43% |
Sales 2024 * | 443M 483M | Sales 2025 * | 719M 784M | Capitalization | 7.14B 7.79B |
---|---|---|---|---|---|
Net income 2024 * | -285M -311M | Net income 2025 * | -10M -10.9M | EV / Sales 2024 * | 17.1 x |
Net Debt 2024 * | 433M 472M | Net Debt 2025 * | 361M 394M | EV / Sales 2025 * | 10.4 x |
P/E ratio 2024 * |
-25.4
x | P/E ratio 2025 * |
-527
x | Employees | 879 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.15% |
Latest transcript on Ascendis Pharma A/S
1 day | +0.16% | ||
1 week | +3.76% | ||
Current month | +0.16% | ||
1 month | -4.10% | ||
3 months | -11.25% | ||
6 months | +30.04% | ||
Current year | +7.43% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
General Counsel | 53 | 07-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.48% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 135.3 | +0.16% | 378,439 |
24-05-31 | 135.1 | -1.71% | 587,045 |
24-05-30 | 137.4 | +3.73% | 511,857 |
24-05-29 | 132.5 | +4.07% | 570,368 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.43% | 7.75B | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- ASND Stock